Advertisements


Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO

The blockbuster public offering pegs Allogene's market value at more than $2 billion. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursd.....»»

Category: europeSource: fortuneOct 11th, 2018

Merck to buy cancer-treatment biotech Tilos Therapeutics for up to $773 million

Merck & Co. Inc. said Monday it was buying privately held biopharmaceutical company Tilos Therapeutics, in a deal that could be valued at up to $773 million. The deal includes an upfront payment and contingent milest.....»»

Category: topSource: marketwatchJun 10th, 2019

Adaptive Biotechnologies files for $230M initial public offering

The Seattle-based biotech company spun out of the Fred Hutchinson Cancer Research Center in 2009 and has independently raised more than $400 million in funding......»»

Category: topSource: bizjournalsMay 30th, 2019

3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400 million

From rare diseases to cancer and NASH, this trio of companies would be the seventh, eighth and nine Bay Area life sciences IPOs this year......»»

Category: topSource: bizjournalsMay 27th, 2019

Athenex just raised $100 million. Here"s what it means

The wheels of progress turn slowly in the biomedical world. But the news this morning that Athenex has scored $100 million in new investment is another sign that big things are coming for the Buffalo-based developer of cancer therapies. Among the .....»»

Category: topSource: bizjournalsMay 6th, 2019

Chinese investors lead another monster round for Menlo Park early cancer detection unicorn

Looking to detect cancer early through a simple blood test, Grail Inc. scored $300 million in new funding from several Chinese investors on top of the $1.2 billion it raised over the past two years. The Menlo Park company, which was rumored to be .....»»

Category: topSource: bizjournalsMay 22nd, 2018

This Biotech Just Had a $903 Million IPO—And It’s Disappointed

Cancer drug maker BeiGene was looking to score $1 billion in its secondary listing in Hon.....»»

Category: europeSource: fortuneAug 2nd, 2018

Cancer-fighting startup lands nearly $19 million as Texas hands out more grants to combat disease

Forbius, a company developing drugs to fight cancer, has scored $18.5 million from the state of Texas to advance its pharmaceuticals. The business operates legally as Formation Biologics Corp. and was founded in Montreal, Canada, in 2011 as a spinoff.....»»

Category: topSource: bizjournalsAug 28th, 2018

Two more Peninsula IPOs tell the story of biotech"s investment boom

And then there were 15. Two Bay Area biotech companies — one that started its first clinical trial in eye diseases in July, the other a pioneer in the fledgling field of hunting down cancer via a simple blood draw — seek to raise $100 million eac.....»»

Category: topSource: bizjournalsSep 8th, 2018

RiverVest leads $40 million venture capital deal

Clayton-based venture capital firm RiverVest Venture Partners has led a $40 million Series B financing round for a Seattle-based biotech company.  The company, OncoResponse, is developing a portfolio of antibodies to high-value targets for cancer t.....»»

Category: topSource: bizjournalsSep 11th, 2018

This cancer-fighting biotech sped from startup to IPO filing in 10 months

The team that took Kite Pharma from a startup re-engineering a patient's own cells to fight cancer to a $12 billion buyout now is seeking a $100 million initial public offering for the South San Francisco company it launched only 10 months ago. Arie B.....»»

Category: topSource: bizjournalsSep 17th, 2018

Pediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPO

Pediatric cancer biot.....»»

Category: topSource: marketwatchSep 21st, 2018

Biotech developing cancer drugs kicks off $13M round with $5K pitch contest win

Rockville-based biotechnology company Remedy Plan Therapeutics took home $5,000 Thursday as the winner of the Maryland Tech Council's inaugural Bio+Tech18 pitch competition. That money will go toward a larger, $13 million round the company is looking .....»»

Category: topSource: bizjournalsSep 21st, 2018

Biotech firm raises $54M to hunt for cancer drugs

Gotham Therapeutics, a Manhattan-based biotech company, has received $54 million in Series A financing to advance research into a novel method of finding oncology drug candidates. The research was... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkOct 10th, 2018

Brainstorm Health: Allogene IPO, Medtronic Hack Concern, Pharmacy Gag Clause

Brainstorm Health Daily: October 11, 2018 Good afternoon, readers--This is Sy. Biotech’s red-hot IPO streak shows no signs of slowing down. In fact, on Thursday, cancer drug maker Allogene Therapeutics pulled .....»»

Category: europeSource: fortuneOct 11th, 2018

This tiny biotech spun a quick $2 billion from $12 million

Endocyte licensed a prostate cancer drug a year ago for an upfront payment of $12 million. Now, it’s being bought by the Swiss pharma giant Novartis for more than $2 billion......»»

Category: topSource: marketwatchOct 18th, 2018

City offers $10M for biotech startups to expand

The city Economic Development Corp. is deploying a $10 million fund to help life sciences companies expand in the city. The first $1 million will go to Quentis Therapeutics, a cancer immunotherapy... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkDec 4th, 2018

City offers $10M for biotech startups to expand

The city Economic Development Corp. is deploying a $10 million fund to help life sciences companies expand in the city. The first $1 million will go to Quentis Therapeutics, a cancer immunotherapy... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkDec 4th, 2018

This Peninsula biotech foresaw deals worth $3 billion. Now it"s lining up a $57 million merger

OncoMed Pharmaceuticals Inc. — whose wide-ranging deals around cancer stem cells once promised to bring in nearly $3 billion — will merge with a London biotech company for $57.4 million, according to terms of the transaction disclosed Wednesday......»»

Category: topSource: bizjournalsDec 5th, 2018

Drug giant Merck acquires Seattle biotech Immune Design for $300 million

The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans......»»

Category: topSource: bizjournalsFeb 21st, 2019

Kango, A Ride-Sharing Service For School-Age Kids, Raises $3.6M In Series A

The kids' ride sharing service Kango scored $3.6 million in Series A, the company announced. National Express, a transportation firm that operates a fleet of more than 25,000 vehicles and serves 600 school districts in 30 states, led the round. read more.....»»

Category: blogSource: benzingaJun 18th, 2019